查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1808049

阿兹海默症诊断和治疗市场（按产品、药物类别、患者人口统计、疾病阶段、最终用户和分销管道）—全球预测 2025-2030

Alzheimer's Disease Diagnostics & Therapeutics Market by Product, Drug Class, Patient Demographics, Disease Stage, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年阿兹海默症诊疗市场规模将达83.5亿美元，2025年将成长至91.2亿美元，复合年增长率为9.50%，到2030年将达到144.1亿美元。

主要市场统计数据
基准年2024年 83.5亿美元
预计2025年 91.2亿美元
预测年份 2030 144.1亿美元
复合年增长率（%） 9.50%

揭示塑造阿兹海默症诊断和治疗市场未来的关键背景、科学要求和行业驱动因素

全球应对阿兹海默症的行动正处于曲折点。分子生物学、神经影像学和生物标记发现等领域的进展正在汇聚，重新定义疾病的诊断和治疗方法。曾经被认为是不可避免的衰退，如今已成为严谨科学探索的主题，新的诊断和治疗方法也不断出现。随着患者、看护者、临床医生和政策制定者呼吁更早发现并采取更有针对性的干预措施，来自学术界、产业界和监管机构的相关人员正在积极行动，以满足这一迫切需求。

确定在快速发展的医疗保健生态系统中重新定义阿兹海默症研究、诊断创新和治疗策略的转型转变

在生物标记检验、新一代影像技术和数位健康整合技术的突破推动下，阿兹海默症领域正在经历一场深刻的变革。在早期，该领域从单纯依赖症状评估转向结合分子诊断技术，能够在临床发病前很久就检测出致病过程。这一转变促进了靶向单株抗体、缓解疾病小分子以及旨在无症状性和前驱期的联合治疗策略的开发。

评估2025年美国关税对阿兹海默症诊断和治疗以及全球供应链动态的多方面影响

美国将于2025年对诊断设备、治疗性生产投入和研究试剂征收新关税，这给阿兹海默症症领域带来了波动。这些政策调整正在影响生物标记、影像诊断和单株抗体成分的筹资策略。曾经依赖高性价比进口产品的机构现在正在评估国内生产能力，并重组供应链，以缓解关税带来的成本上涨。

探索推动细分的阿兹海默症解决方案的关键见解，包括产品、药物类别、患者人口统计、疾病阶段、最终用户和分销管道

详细的細項分析可以清楚展现阿兹海默症治疗领域技术创新、投资和应用的整合。依产品类型检验市场发现，生物标记、基因检测等诊断方式，CT、MRI、EEG 和 PET 等影像技术，以及简易精神状态检查等神经心理学测试，正与联合治疗、药物疗法和认知刺激疗法等非药物干预等治疗手段共同发展。血液生物标记和脑脊髓液检测正成为互补的诊断手段，增强早期检测能力。

探索美洲、欧洲、中东和非洲以及亚太地区阿兹海默症护理和研究的区域差异和战略机会

要了解阿兹海默症的各类发展状况，区域观点至关重要。在美洲，强大的医疗基础设施、广泛的学术合作以及对生物标记研究的大量投入，正在加速先进诊断检测和治疗测试的普及。该地区率先开发了基于血液的生物标记检测组，并广泛利用远端医疗网络来扩大患者（尤其是在贫困农村社区）的医疗服务覆盖范围。

分析重新定义阿兹海默症诊断和治疗市场的关键产业参与者的策略发展、创新组合和合作努力

阿兹海默症诊断和治疗行业的特点是生命科学创新者、生物技术先驱和成熟製药公司的活力组合。主要企业已经建立了整合生物标记发现、成像药物开发和新一代抗体工程的综合研发平台。他们的策略部署包括与学术中心签订合作研究协议、建立合资企业以扩大生产规模，以及签署许可协议以扩展产品系列。

制定实用、前瞻性的建议，协助产业领导者推动阿兹海默症的研究、诊断和治疗策略

产业领导者必须采取多管齐下的策略，以充分利用不断发展的科学发现和不断变化的政策环境。首先，将血液生物标记与神经影像学和基因检测结合，可以优先考虑早期介入平台，加快临床试验入组，并提高诊断信心。整合分子生物学家、资料科学家和神经心理学家的跨学科联盟的发展，将有助于开发下一代筛检方案和数位诊断工具。

了解严格的老年痴呆症市场调查方法，该方法结合了初步访谈、二次资料分析和专家检验。

本次市场分析整合了严谨的多阶段调查方法。首先，我们进行了全面的二次审查，涵盖同行评审文献、临床试验註册库、监管备案文件和专有专利资料库，以绘製诊断技术和治疗方案的演变图。我们提取了关键绩效指标，包括诊断准确率、治疗反应率和临床试验入组指标，以建立比较基准。

透过总结关键发现、策略意义和未来展望来评估阿兹海默症诊断和治疗市场格局

本执行摘要概述了阿兹海默症诊疗领域技术创新、政策转变和策略性细分之间的动态相互作用。从先进生物标誌物检测和人工智慧成像的兴起，到对价格调整的策略反应，该领域呈现出快速迭代和协同推进的特征。本摘要按产品、药物类别、患者人口统计、疾病分期、最终用户和分销管道进行详细细分，揭示了根据不同的临床和市场需求量身定制解决方案的复杂性和潜力。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 开发针对阿兹海默症多种途径的联合治疗
  • 生物标记发现的进展改善了阿兹海默症的早期诊断
  • 加大对基因研究的投入，寻找阿兹海默症治疗的新标靶
  • 合作与伙伴关係激增，加速阿兹海默症药物研发
  • 基因治疗技术作为治疗阿兹海默症的一种有前景的方法的出现
  • 神经发炎作为阿兹海默症研究的治疗标靶越来越受到关注
  • 扩展数位健康工具，用于远端系统管理阿兹海默症患者
  • 非侵入性影像技术在阿兹海默症检测的应用日益增多
  • 将人工智慧融入阿兹海默症的诊断和监测
  • 个人化医疗方法在治疗阿兹海默症的出现

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章：2025年美国关税的累积影响

第八章阿兹海默症诊断和治疗市场（按产品）

  • 诊断
    • 生物标誌物
      • 血液生物标记
      • 脑脊髓液（CSF）生物标记物
    • 基因检测
    • 影像技术
      • 电脑断层扫描（CT）
      • 脑电图（EEG）
      • 磁振造影（MRI）
      • 正子断层扫描（PET）
    • 神经心理学测试
      • 确认患有失智症
      • 简易精神状态检查表
      • 蒙特娄认知评估
      • 神经精神评估调查问卷
  • 治疗药物
    • 联合治疗
    • 药物治疗
    • 非药物治疗
      • 行为干预
      • 认知刺激疗法

第九章阿兹海默症诊断和治疗市场（按药物类别）

  • 胆碱酯酶抑制剂
    • 多奈哌齐
    • Galantamine
    • Rivastigmine
  • 单株抗体
    • 阿杜卡努马
    • 多纳尼单抗
    • 莱卡尼单抗
  • NMDA受体拮抗剂

第 10 章阿兹海默症诊断和治疗市场（按患者人口统计）

  • 65-74岁
  • 75至84岁
  • 85岁或以上
  • 65岁以下

第 11 章阿兹海默症诊断和治疗市场（按疾病阶段）

  • 最初的
  • 晚期
  • 中期

第 12 章阿兹海默症诊断与治疗市场（按最终用户）

  • 学术研究机构
  • 诊断中心
  • 居家照护环境
  • 医院和诊所

第 13 章阿兹海默症诊断与治疗市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

14.美国阿兹海默阿兹海默症诊断与治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 欧洲、中东和非洲阿兹海默症诊断和治疗市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

16. 亚太地区阿兹海默症诊断与治疗市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbvie Inc.
    • AC Immune SA
    • Alector, Inc.
    • Alzheon, Inc.
    • Amylyx Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Aurobindo Pharma Limited
    • Biogen Inc.
    • BioXcel Therapeutics Inc.
    • Bristol-Myers Squibb Company
    • Cognoptix Inc.
    • Corium Inc.
    • Denali Therapeutics Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Grifols, SA
    • H. Lundbeck A/S
    • Lupin Limited
    • Luye Pharma Group Ltd.
    • Merck & Co. Inc.
    • Muna Therapeutics
    • Novartis AG
    • Quest Diagnostics Incorporated
    • Sanofi SA
    • Siemens Healthineers AG
    • Takeda Pharmaceutical Company Limited
    • TauRx Therapeutics Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Voyager Therapeutics, Inc.
    • Zydus Lifesciences Limited
    • Danaher Corporation
    • Johnson & Johnson Services, Inc.
    • Thermo Fisher Scientific Inc.
    • GE Healthcare

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

Product Code: MRR-742BD517AA98

The Alzheimer's Disease Diagnostics & Therapeutics Market was valued at USD 8.35 billion in 2024 and is projected to grow to USD 9.12 billion in 2025, with a CAGR of 9.50%, reaching USD 14.41 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 8.35 billion
Estimated Year [2025] USD 9.12 billion
Forecast Year [2030] USD 14.41 billion
CAGR (%) 9.50%

Unveiling the Critical Context, Scientific Imperatives, and Industry Drivers Shaping the Future of Alzheimer's Disease Diagnostics and Therapeutics

The global response to Alzheimer's disease has reached an inflection point. Advances in molecular biology, neuroimaging, and biomarker discovery are converging to redefine how the disease is diagnosed and treated. What was once considered an inevitable decline is now subject to rigorous scientific inquiry that is unlocking new diagnostic modalities and therapeutic approaches. With patients, caregivers, clinicians, and policymakers demanding earlier detection and more precise interventions, stakeholders across academia, industry, and regulatory bodies are mobilizing to meet this pressing need.

In recent years, diagnostic paradigms have shifted from purely clinical assessments to integrated models that leverage blood-based biomarkers, cerebrospinal fluid analyses, high-resolution magnetic resonance imaging, positron emission tomography, and sophisticated neuropsychological batteries such as the Montreal Cognitive Assessment and the Ascertain Dementia 8 instrument. At the same time, the therapeutic landscape is evolving beyond conventional drug monotherapies to embrace combination regimes, monoclonal antibodies targeting amyloid and tau, and non-pharmacological approaches like cognitive stimulation therapy and behavioral interventions.

This introduction sets the stage for an in-depth exploration of transformative shifts, tariff implications, segmentation insights, regional dynamics, and strategic recommendations. By synthesizing the latest data, expert perspectives, and methodological rigor, this report aims to equip decision-makers with the clarity and foresight needed to navigate the complex Alzheimer's ecosystem and to accelerate innovation for the millions of individuals and families affected worldwide.

Identifying the Transformative Shifts Redefining Alzheimer's Research, Diagnostic Innovation, and Therapeutic Strategies in a Rapidly Evolving Healthcare Ecosystem

The Alzheimer's disease arena is witnessing a profound transformation driven by breakthroughs in biomarker validation, next-generation imaging, and digital health integration. Early on, the field pivoted from relying solely on symptomatic assessments to embracing molecular diagnostics that detect pathogenic processes long before clinical onset. This shift has catalyzed the development of targeted monoclonal antibodies, disease-modifying small molecules, and combination strategies that aim to intervene at asymptomatic and prodromal stages.

Simultaneously, the integration of artificial intelligence and machine learning into imaging techniques such as MRI, CT, and PET scans is enabling unprecedented precision in lesion detection and progression monitoring. Genetic testing advancements are refining risk stratification frameworks, while neuropsychological testing innovations are enhancing cognitive profiling with tools like the Neuropsychiatric Inventory Questionnaire. On the therapeutic side, the blending of non-drug modalities-including cognitive stimulation and behavioral interventions-with pharmacological regimens is reshaping patient care models.

Healthcare systems are adapting to these innovations by expanding homecare settings, upgrading diagnostic center capabilities, and fostering cross-sector collaborations between hospitals, academic institutions, and technology partners. These dynamics are creating an ecosystem in which data interoperability, regulatory agility, and patient-centric design are increasingly recognized as critical enablers of successful Alzheimer's interventions. This section unpacks these transformative shifts, illustrating how interconnected advancements are redefining the research, development, and delivery of diagnostics and therapeutics in Alzheimer's disease.

Evaluating the Multifaceted Consequences of the 2025 United States Tariffs on Alzheimer's Disease Diagnostics, Therapeutics, and Global Supply Chain Dynamics

The introduction of new tariffs on diagnostic equipment, therapeutics manufacturing inputs, and research reagents by the United States in 2025 has rippled across the Alzheimer's disease landscape. These policy adjustments have influenced sourcing strategies for biomarkers, imaging agents, and monoclonal antibody components. Facilities that once relied on cost-effective imports are now evaluating domestic production capabilities and realigning supply chains to mitigate tariff-driven cost escalations.

On the diagnostics front, increased duties on specialized imaging hardware and cerebrospinal fluid assay kits have prompted diagnostic centers and academic research institutes to reassess capital expenditure and maintenance budgets. This in turn has accelerated the exploration of blood-based biomarker assays and decentralized testing models that reduce reliance on high-cost imports. Within therapeutics, the tariffs have impacted the raw materials essential for producing cholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies such as aducanumab and lecanemab.

The cumulative effect has been a strategic pivot toward regional manufacturing hubs and localized distribution channels. Online and retail pharmacies are adapting to ensure patient access despite cost pressures, while hospital pharmacies are forging partnerships with domestic suppliers. Regulatory bodies are also streamlining approval pathways to encourage local production. As a result, stakeholders are balancing the need to maintain affordability and accessibility with the imperative to invest in innovation. This section delves into the nuanced implications of the 2025 tariffs and how they are driving adaptive strategies across the Alzheimer's diagnostics and therapeutics ecosystem.

Deciphering Core Insights from Product, Drug Class, Patient Demographics, Disease Stages, End Users, and Distribution Channel Segmentations Driving Alzheimer's Solutions

An in-depth segmentation analysis provides a granular view of where innovation, investment, and adoption converge in Alzheimer's disease care. Examining the market by product type reveals that diagnostic modalities-comprising biomarkers, genetic tests, imaging techniques such as CT, MRI, EEG, and PET, and neuropsychological batteries like the Mini-Mental State Exam-are advancing alongside therapeutic pillars that include combination therapies, drug treatments, and non-drug interventions such as cognitive stimulation therapy. Blood-based biomarkers and cerebrospinal fluid assays are emerging as complementary diagnostic streams that enhance early detection capabilities.

When viewed through the lens of drug class, cholinesterase inhibitors such as donepezil, galantamine, and rivastigmine continue to serve as foundational therapies, while monoclonal antibodies including aducanumab, donanemab, and lecanemab are redefining disease-modifying treatment approaches. NMDA receptor antagonists also play a pivotal role in addressing symptomatic management. Patient demographic segmentation highlights the nuanced needs of those aged 65 to 74 years, 75 to 84 years, above 85 years, and the emerging considerations for individuals below 65 years who may present early-onset pathology.

Stage-based differentiation underscores the contrast between early-stage, middle-stage, and late-stage Alzheimer's, each demanding tailored intervention strategies and care delivery models. End users-spanning academic and research institutes, diagnostic centers, homecare settings, and hospitals and clinics-drive distinct adoption cycles, while distribution channels comprising hospital, online, and retail pharmacies shape accessibility and patient engagement. This comprehensive segmentation lens illuminates the multifaceted pathways through which diagnostics and therapeutics are researched, delivered, and integrated into patient care.

Uncovering Regional Variations and Strategic Opportunities across Americas, Europe Middle East and Africa, and Asia Pacific for Alzheimer's Care and Research

Regional perspectives are paramount to understanding the heterogeneous Alzheimer's disease landscape. In the Americas, robust healthcare infrastructure, extensive academic collaborations, and substantial investment in biomarker research have accelerated the adoption of advanced diagnostic assays and therapeutic trials. This region is pioneering blood-based biomarker panels and leveraging widespread telehealth networks to expand patient access, particularly in under-resourced rural communities.

Within Europe, Middle East, and Africa, regulatory convergence and cross-border research consortia are driving standardization of imaging protocols and genetic testing frameworks. Nations are investing in the integration of neuropsychological testing instruments, such as the Montreal Cognitive Assessment, into primary care pathways. Concurrently, localized production of monoclonal antibodies and small molecules is gaining traction, supported by favorable policy incentives and public-private partnerships.

In the Asia-Pacific region, rapid demographic aging, burgeoning homecare models, and digital health innovations are propelling demand for decentralized diagnostic tools and non-drug interventions. Behavioral interventions and cognitive stimulation programs are being adapted to local cultural contexts, while emerging biotech hubs are forging alliances with global pharmaceutical companies to accelerate clinical development. Each region's unique regulatory landscape, patient demographics, and healthcare delivery infrastructure create differentiated opportunities and challenges. This section explores these regional nuances, offering strategic guidance on how stakeholders can tailor their approaches to maximize impact and accessibility.

Analyzing Key Industry Players' Strategic Footprints, Innovation Portfolios, and Collaborative Efforts Redefining Alzheimer's Diagnostics and Therapeutics Markets

The Alzheimer's diagnostics and therapeutics sector is characterized by a dynamic mix of life science innovators, biotechnology pioneers, and established pharmaceutical firms. Leading companies have established comprehensive R&D platforms that integrate biomarker discovery, imaging agent development, and next-generation antibody engineering. Their strategic footprints often include collaborative research agreements with academic centers, joint ventures for manufacturing scale-up, and licensing arrangements to broaden their product portfolios.

In diagnostics, firms specializing in blood-based assays are forging partnerships with neuroimaging companies to develop multimodal screening solutions. Imaging technology providers are embedding artificial intelligence algorithms to enhance lesion detection and predictive analytics. On the therapeutics front, biotechnology companies focused on monoclonal antibodies are investing heavily in clinical pipeline expansion, while pharmaceutical incumbents are strengthening their small molecule and combination therapy offerings to maintain competitive positioning.

This landscape is further shaped by emerging players that are commercializing digital cognitive assessment platforms and novel non-drug interventions. Their agility in navigating regulatory surfaces and digital health approval pathways positions them as potential disruptors. Collectively, these enterprises are influencing pricing models, market access strategies, and global distribution frameworks. This section delves into the strategic initiatives, innovation trajectories, and collaborative networks of key companies, illuminating how they are driving the evolution of Alzheimer's disease diagnostics and therapeutics.

Formulating Practical and Forward-Looking Recommendations to Empower Industry Leaders in Advancing Alzheimer's Disease Research, Diagnostics, and Treatment Strategies

Industry leaders must adopt a multifaceted strategy to harness evolving scientific discoveries and shifting policy landscapes. First, prioritizing early-stage intervention platforms by integrating blood-based biomarkers with neuroimaging and genetic testing can accelerate clinical trial enrollment and improve diagnostic confidence. Establishing cross-disciplinary consortia that unify molecular biologists, data scientists, and neuropsychologists will catalyze the development of next-generation screening panels and digital diagnostic tools.

Second, diversifying therapeutic portfolios through strategic acquisitions or licensing deals can enhance access to novel monoclonal antibodies and non-drug interventions. By forging partnerships with academic research institutes and biotech startups, companies can leverage precompetitive data, share development risks, and expedite regulatory submissions. Simultaneously, investing in regional manufacturing capabilities and supply chain resilience will mitigate tariff impacts and ensure consistent product availability across diverse markets.

Third, adopting a patient-centric approach that tailors care pathways to demographic and disease-stage nuances will differentiate value propositions. This includes customizing treatment regimens for patients aged 65 to 74 years versus those above 85 years, and integrating cognitive stimulation therapy within homecare settings. Finally, embedding real-world evidence collection within diagnostic and therapeutic roll-outs will strengthen payer negotiations and support reimbursement frameworks. By executing these recommendations, industry stakeholders can align innovation with market imperatives, delivering sustainable growth and improved patient outcomes.

Detailing the Rigorous Research Methodology Integrating Primary Interviews, Secondary Data Analysis, and Expert Validation for Alzheimer's Market Study

This market analysis integrates a rigorous multi-stage research methodology. Initially, a comprehensive secondary review was conducted, encompassing peer-reviewed literature, clinical trial registries, regulatory filings, and proprietary patent databases to map the evolution of diagnostic technologies and therapeutic pipelines. Key performance indicators, such as diagnostic accuracy, treatment response rates, and clinical trial enrollment metrics, were extracted to establish comparative benchmarks.

Subsequently, primary research involved in-depth interviews with leading neurologists, research scientists, regulatory experts, and supply chain executives. These qualitative insights provided context on adoption barriers, reimbursement challenges, and strategic collaboration models. Concurrently, quantitative surveys were administered to diagnostic centers, hospitals, pharmacies, and homecare providers to capture deployment trends across different end-user segments and distribution channels.

Data triangulation ensured the validation of findings by cross-referencing primary inputs with secondary data points and incorporating feedback loops from industry advisory panels. This iterative validation process underpinned the development of segmentation frameworks, tariff impact assessments, and regional insights. Finally, an internal expert review panel, comprising neuropsychologists, pharmacologists, and health economists, scrutinized the analysis for methodological robustness and factual accuracy. This structured approach guarantees that the conclusions and recommendations presented are grounded in comprehensive evidence and reflective of the current Alzheimer's disease diagnostics and therapeutics ecosystem.

Synthesizing Critical Findings, Strategic Implications, and Future Outlook to Conclude the Alzheimer's Disease Diagnostics and Therapeutics Landscape Assessment

This executive summary has mapped the dynamic interplay of technological innovation, policy shifts, and strategic segmentation within Alzheimer's disease diagnostics and therapeutics. From the emergence of advanced biomarker assays and AI-enhanced imaging modalities to the strategic responses to tariff adjustments, the landscape is characterized by rapid iteration and collaborative advancement. Detailed segmentation across product types, drug classes, patient demographics, disease stages, end users, and distribution channels has revealed the complexity and opportunity inherent in tailoring solutions to diverse clinical and market needs.

Regional insights have underscored the importance of localized strategies, whether it be the Americas' emphasis on telehealth and rural access, the EMEA region's drive for regulatory harmonization, or the Asia-Pacific focus on decentralization and cultural adaptation of non-drug therapies. The strategic footprints of leading companies, combined with the actionable recommendations outlined, form a roadmap for stakeholders seeking to navigate competitive pressures, regulatory demands, and unmet clinical needs.

Looking ahead, the convergence of precision diagnostics, personalized therapeutics, and data-driven decision support systems is poised to accelerate disease modification efforts and improve patient outcomes. This conclusion synthesizes the critical findings and underscores the imperative for continued collaboration, innovation, and patient-centric focus as the Alzheimer's disease ecosystem evolves.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of combination therapies targeting multiple Alzheimer's disease pathways
  • 5.2. Advancements in biomarker discovery fueling early Alzheimer's diagnosis accuracy
  • 5.3. Increasing investments in genetic research to identify new targets for Alzheimer's treatments
  • 5.4. Surging collaborations and partnerships to accelerate Alzheimer's drug development
  • 5.5. Rise of gene therapy techniques as a promising approach for treating Alzheimer's disease
  • 5.6. Increasing focus on neuroinflammation as a therapeutic target in Alzheimer's research
  • 5.7. Expansion of digital health tools for remote Alzheimer's patient management
  • 5.8. Growing adoption of non-invasive imaging techniques for Alzheimer's detection
  • 5.9. Integration of artificial intelligence in Alzheimer's disease diagnostics and monitoring
  • 5.10. Emergence of personalized medicine approaches in Alzheimer's therapeutic development

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product

  • 8.1. Introduction
  • 8.2. Diagnostics
    • 8.2.1. Biomarkers
      • 8.2.1.1. Blood-Based Biomarkers
      • 8.2.1.2. Cerebrospinal Fluid (CSF) Biomarkers
    • 8.2.2. Genetic Testing
    • 8.2.3. Imaging Techniques
      • 8.2.3.1. Computed Tomography (CT) Scans
      • 8.2.3.2. Electroencephalogram (EEG)
      • 8.2.3.3. Magnetic Resonance Imaging (MRI)
      • 8.2.3.4. Positron Emission Tomography (PET)
    • 8.2.4. Neuropsychological Testing
      • 8.2.4.1. Ascertain Dementia 8
      • 8.2.4.2. Mini-Mental State Exam
      • 8.2.4.3. Montreal Cognitive Assessment
      • 8.2.4.4. Neuropsychiatric Inventory Questionnaire
  • 8.3. Therapeutics
    • 8.3.1. Combination Therapies
    • 8.3.2. Drug Therapies
    • 8.3.3. Non-Drug Therapies
      • 8.3.3.1. Behavioral Interventions
      • 8.3.3.2. Cognitive Stimulation Therapy

9. Alzheimer's Disease Diagnostics & Therapeutics Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Cholinesterase Inhibitors
    • 9.2.1. Donepezil
    • 9.2.2. Galantamine
    • 9.2.3. Rivastigmine
  • 9.3. Monoclonal Antibodies
    • 9.3.1. Aducanumab
    • 9.3.2. Donanemab
    • 9.3.3. Lecanemab
  • 9.4. NMDA Receptor Antagonists

10. Alzheimer's Disease Diagnostics & Therapeutics Market, by Patient Demographics

  • 10.1. Introduction
  • 10.2. 65-74 Years
  • 10.3. 75-84 Years
  • 10.4. Above 85 Years
  • 10.5. Below 65 Years

11. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage

  • 11.1. Introduction
  • 11.2. Early-Stage Alzheimer's
  • 11.3. Late-Stage Alzheimer's
  • 11.4. Middle-Stage Alzheimer's

12. Alzheimer's Disease Diagnostics & Therapeutics Market, by End User

  • 12.1. Introduction
  • 12.2. Academic & Research Institutes
  • 12.3. Diagnostic Centers
  • 12.4. Homecare Settings
  • 12.5. Hospitals & Clinics

13. Alzheimer's Disease Diagnostics & Therapeutics Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacies
  • 13.3. Online Pharmacies
  • 13.4. Retail Pharmacies

14. Americas Alzheimer's Disease Diagnostics & Therapeutics Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Alzheimer's Disease Diagnostics & Therapeutics Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Alzheimer's Disease Diagnostics & Therapeutics Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbvie Inc.
    • 17.3.2. AC Immune SA
    • 17.3.3. Alector, Inc.
    • 17.3.4. Alzheon, Inc.
    • 17.3.5. Amylyx Pharmaceuticals, Inc.
    • 17.3.6. AstraZeneca PLC
    • 17.3.7. Aurobindo Pharma Limited
    • 17.3.8. Biogen Inc.
    • 17.3.9. BioXcel Therapeutics Inc.
    • 17.3.10. Bristol-Myers Squibb Company
    • 17.3.11. Cognoptix Inc.
    • 17.3.12. Corium Inc.
    • 17.3.13. Denali Therapeutics Inc.
    • 17.3.14. Eisai Co., Ltd.
    • 17.3.15. Eli Lilly and Company
    • 17.3.16. F. Hoffmann-La Roche AG
    • 17.3.17. Grifols, S.A.
    • 17.3.18. H. Lundbeck A/S
    • 17.3.19. Lupin Limited
    • 17.3.20. Luye Pharma Group Ltd.
    • 17.3.21. Merck & Co. Inc.
    • 17.3.22. Muna Therapeutics
    • 17.3.23. Novartis AG
    • 17.3.24. Quest Diagnostics Incorporated
    • 17.3.25. Sanofi S.A.
    • 17.3.26. Siemens Healthineers AG
    • 17.3.27. Takeda Pharmaceutical Company Limited
    • 17.3.28. TauRx Therapeutics Ltd.
    • 17.3.29. Teva Pharmaceutical Industries Ltd.
    • 17.3.30. Voyager Therapeutics, Inc.
    • 17.3.31. Zydus Lifesciences Limited
    • 17.3.32. Danaher Corporation
    • 17.3.33. Johnson & Johnson Services, Inc.
    • 17.3.34. Thermo Fisher Scientific Inc.
    • 17.3.35. GE Healthcare

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET: RESEARCHAI
  • FIGURE 28. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET: RESEARCHCONTACTS
  • FIGURE 30. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD-BASED BIOMARKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF) BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CEREBROSPINAL FLUID (CSF) BIOMARKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ELECTROENCEPHALOGRAM (EEG), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ASCERTAIN DEMENTIA 8, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ASCERTAIN DEMENTIA 8, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MINI-MENTAL STATE EXAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MINI-MENTAL STATE EXAM, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONTREAL COGNITIVE ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONTREAL COGNITIVE ASSESSMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHIATRIC INVENTORY QUESTIONNAIRE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BEHAVIORAL INTERVENTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BEHAVIORAL INTERVENTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE STIMULATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE STIMULATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADUCANUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ADUCANUMAB, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONANEMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DONANEMAB, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LECANEMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LECANEMAB, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 65-74 YEARS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY 75-84 YEARS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ABOVE 85 YEARS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BELOW 65 YEARS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY-STAGE ALZHEIMER'S, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LATE-STAGE ALZHEIMER'S, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MIDDLE-STAGE ALZHEIMER'S, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 143. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
  • TABLE 145. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 147. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 189. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 190. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 191. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 192. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2030 (USD MILLION)
  • TABLE 193. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 194. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2025-2030 (USD MILLION)
  • TABLE 195. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 197. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
  • TABLE 205. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 206. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 207. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 208. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
  • TABLE 209. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 211. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 213. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 215. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2030 (USD MILLION)
  • TABLE 221. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 222. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2025-2030 (USD MILLION)
  • TABLE 223. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 224. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 225. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 227. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 228. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 229. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
  • TABLE 233. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 235. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
  • TABLE 237. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 239. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 241. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 243. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 245. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 246. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 247. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2024 (USD MILLION)
  • TABLE 248. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNIQUES, 2025-2030 (USD MILLION)
  • TABLE 249. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2018-2024 (USD MILLION)
  • TABLE 250. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NEUROPSYCHOLOGICAL TESTING, 2025-2030 (USD MILLION)
  • TABLE 251. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
  • TABLE 252. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
  • TABLE 253. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 254. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-DRUG THERAPIES, 2025-2030 (USD MILLION)
  • TABLE 255. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 256. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 257. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITOR